Acute lymphoblastic leukemia and lymphoma in adults

Anjali S. Advani, Hetty E. Carraway, Judith Karp, Ivan D. Horak

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Almost 5500 cases of acute lymphoblastic leukemia (ALL) were predicted to be diagnosed in 2008 in the United States,1 approximately one-third of which would be in adults. Acute lymphoblastic leukemia is a heterogeneous group of potentially curable lymphoid disorders that results from monoclonal proliferation and accumulation of lymphoblasts in the bone marrow, peripheral blood, and other organs. Acute lymphoblastic leukemia is a sharply contrasting disease in pediatric and adult populations. Excellent medical progress in the therapy of childhood ALL has been made, with steady improvement over the past five decades; combination chemotherapy and central nervous system (CNS) prophylaxis have improved the cure rate of ALL in children from 5 percent in 1950 to 85 percent in 2000.2 Following the lead from the pediatric experience, doseintense multiagent regimens administered to adult patients with ALL now achieve remission rates exceeding 80 percent but with 5-year survival of only around 40 percent.3 Current therapy for adults with ALL has become increasingly dependent on patient- and disease-specific characteristics. Therefore, proper diagnostic workup with leukemic-cell phenotyping, cytogenetics, and molecular diagnosis, including identification of the BCR-ABL fusion gene, is critical for prognostication and for guiding appropriate therapeutic choice. Progress has been made in moving toward tailored treatment that is more age specific and biologically relevant. Recent results suggest that applying age- and risk-adopted therapeutic strategies using several components of complex pediatric protocols may lead to improved outcome in adult patients with ALL. Participation in well-designed clinical trials is critical for future progress in the management of adult patients with ALL.

Original languageEnglish (US)
Title of host publicationThe Lymphoid Neoplasms 3ed
PublisherCRC Press
Pages1092-1122
Number of pages31
ISBN (Electronic)9781444113228
ISBN (Print)9780340809471
DOIs
StatePublished - Jan 1 2010

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Therapeutics
Gene Fusion
Combination Drug Therapy
Cytogenetics
Central Nervous System
Bone Marrow
Clinical Trials
Survival
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advani, A. S., Carraway, H. E., Karp, J., & Horak, I. D. (2010). Acute lymphoblastic leukemia and lymphoma in adults. In The Lymphoid Neoplasms 3ed (pp. 1092-1122). CRC Press. https://doi.org/10.1201/b13424

Acute lymphoblastic leukemia and lymphoma in adults. / Advani, Anjali S.; Carraway, Hetty E.; Karp, Judith; Horak, Ivan D.

The Lymphoid Neoplasms 3ed. CRC Press, 2010. p. 1092-1122.

Research output: Chapter in Book/Report/Conference proceedingChapter

Advani, AS, Carraway, HE, Karp, J & Horak, ID 2010, Acute lymphoblastic leukemia and lymphoma in adults. in The Lymphoid Neoplasms 3ed. CRC Press, pp. 1092-1122. https://doi.org/10.1201/b13424
Advani AS, Carraway HE, Karp J, Horak ID. Acute lymphoblastic leukemia and lymphoma in adults. In The Lymphoid Neoplasms 3ed. CRC Press. 2010. p. 1092-1122 https://doi.org/10.1201/b13424
Advani, Anjali S. ; Carraway, Hetty E. ; Karp, Judith ; Horak, Ivan D. / Acute lymphoblastic leukemia and lymphoma in adults. The Lymphoid Neoplasms 3ed. CRC Press, 2010. pp. 1092-1122
@inbook{7451709d474b4d7fb630e4f0a77f043f,
title = "Acute lymphoblastic leukemia and lymphoma in adults",
abstract = "Almost 5500 cases of acute lymphoblastic leukemia (ALL) were predicted to be diagnosed in 2008 in the United States,1 approximately one-third of which would be in adults. Acute lymphoblastic leukemia is a heterogeneous group of potentially curable lymphoid disorders that results from monoclonal proliferation and accumulation of lymphoblasts in the bone marrow, peripheral blood, and other organs. Acute lymphoblastic leukemia is a sharply contrasting disease in pediatric and adult populations. Excellent medical progress in the therapy of childhood ALL has been made, with steady improvement over the past five decades; combination chemotherapy and central nervous system (CNS) prophylaxis have improved the cure rate of ALL in children from 5 percent in 1950 to 85 percent in 2000.2 Following the lead from the pediatric experience, doseintense multiagent regimens administered to adult patients with ALL now achieve remission rates exceeding 80 percent but with 5-year survival of only around 40 percent.3 Current therapy for adults with ALL has become increasingly dependent on patient- and disease-specific characteristics. Therefore, proper diagnostic workup with leukemic-cell phenotyping, cytogenetics, and molecular diagnosis, including identification of the BCR-ABL fusion gene, is critical for prognostication and for guiding appropriate therapeutic choice. Progress has been made in moving toward tailored treatment that is more age specific and biologically relevant. Recent results suggest that applying age- and risk-adopted therapeutic strategies using several components of complex pediatric protocols may lead to improved outcome in adult patients with ALL. Participation in well-designed clinical trials is critical for future progress in the management of adult patients with ALL.",
author = "Advani, {Anjali S.} and Carraway, {Hetty E.} and Judith Karp and Horak, {Ivan D.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1201/b13424",
language = "English (US)",
isbn = "9780340809471",
pages = "1092--1122",
booktitle = "The Lymphoid Neoplasms 3ed",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Acute lymphoblastic leukemia and lymphoma in adults

AU - Advani, Anjali S.

AU - Carraway, Hetty E.

AU - Karp, Judith

AU - Horak, Ivan D.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Almost 5500 cases of acute lymphoblastic leukemia (ALL) were predicted to be diagnosed in 2008 in the United States,1 approximately one-third of which would be in adults. Acute lymphoblastic leukemia is a heterogeneous group of potentially curable lymphoid disorders that results from monoclonal proliferation and accumulation of lymphoblasts in the bone marrow, peripheral blood, and other organs. Acute lymphoblastic leukemia is a sharply contrasting disease in pediatric and adult populations. Excellent medical progress in the therapy of childhood ALL has been made, with steady improvement over the past five decades; combination chemotherapy and central nervous system (CNS) prophylaxis have improved the cure rate of ALL in children from 5 percent in 1950 to 85 percent in 2000.2 Following the lead from the pediatric experience, doseintense multiagent regimens administered to adult patients with ALL now achieve remission rates exceeding 80 percent but with 5-year survival of only around 40 percent.3 Current therapy for adults with ALL has become increasingly dependent on patient- and disease-specific characteristics. Therefore, proper diagnostic workup with leukemic-cell phenotyping, cytogenetics, and molecular diagnosis, including identification of the BCR-ABL fusion gene, is critical for prognostication and for guiding appropriate therapeutic choice. Progress has been made in moving toward tailored treatment that is more age specific and biologically relevant. Recent results suggest that applying age- and risk-adopted therapeutic strategies using several components of complex pediatric protocols may lead to improved outcome in adult patients with ALL. Participation in well-designed clinical trials is critical for future progress in the management of adult patients with ALL.

AB - Almost 5500 cases of acute lymphoblastic leukemia (ALL) were predicted to be diagnosed in 2008 in the United States,1 approximately one-third of which would be in adults. Acute lymphoblastic leukemia is a heterogeneous group of potentially curable lymphoid disorders that results from monoclonal proliferation and accumulation of lymphoblasts in the bone marrow, peripheral blood, and other organs. Acute lymphoblastic leukemia is a sharply contrasting disease in pediatric and adult populations. Excellent medical progress in the therapy of childhood ALL has been made, with steady improvement over the past five decades; combination chemotherapy and central nervous system (CNS) prophylaxis have improved the cure rate of ALL in children from 5 percent in 1950 to 85 percent in 2000.2 Following the lead from the pediatric experience, doseintense multiagent regimens administered to adult patients with ALL now achieve remission rates exceeding 80 percent but with 5-year survival of only around 40 percent.3 Current therapy for adults with ALL has become increasingly dependent on patient- and disease-specific characteristics. Therefore, proper diagnostic workup with leukemic-cell phenotyping, cytogenetics, and molecular diagnosis, including identification of the BCR-ABL fusion gene, is critical for prognostication and for guiding appropriate therapeutic choice. Progress has been made in moving toward tailored treatment that is more age specific and biologically relevant. Recent results suggest that applying age- and risk-adopted therapeutic strategies using several components of complex pediatric protocols may lead to improved outcome in adult patients with ALL. Participation in well-designed clinical trials is critical for future progress in the management of adult patients with ALL.

UR - http://www.scopus.com/inward/record.url?scp=85056045128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056045128&partnerID=8YFLogxK

U2 - 10.1201/b13424

DO - 10.1201/b13424

M3 - Chapter

SN - 9780340809471

SP - 1092

EP - 1122

BT - The Lymphoid Neoplasms 3ed

PB - CRC Press

ER -